As AMPK activators, such as metformin, are widely used for diabetes type II in the clinical arena (38), further insight into the exact biological mechanism of AMPK may help to provide better clarity as to the potential pharmacological targeting of AMPK in sepsis. This evidence concerns the gene PRKAA1 and type 2 diabetes mellitus.